Market PotentialZUSDURI could reach blockbuster status in the 2030 time frame due to the larger size of the NMIBC target market and its current status as the only approved pharmacotherapy for recurrent LG-IR-NMIBC.
Physician InterestZUSDURI's impressive profile is resonating well with physicians, who have shown significant interest in prescribing it.
Product ApprovalThe FDA approval of ZUSDURI, the first and only medication for recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer, represents a highly welcome result.